

Luis M Blanco-Colio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3142669/publications.pdf>

Version: 2024-02-01

41
papers

1,413
citations

361045

20
h-index

329751

37
g-index

41
all docs

41
docs citations

41
times ranked

1825
citing authors

#	ARTICLE	IF	CITATIONS
1	The CD163-expressing macrophages recognize and internalize TWEAK. <i>Atherosclerosis</i> , 2009, 207, 103-110.	0.4	129
2	Tumor Necrosis Factor- α -Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in ApoE-Knockout Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 2061-2068.	1.1	101
3	Fn14 Is Upregulated in Cytokine-Stimulated Vascular Smooth Muscle Cells and Is Expressed in Human Carotid Atherosclerotic Plaques. <i>Stroke</i> , 2006, 37, 2044-2053.	1.0	95
4	NF- κ B Activation and Fas Ligand Overexpression in Blood and Plaques of Patients With Carotid Atherosclerosis. <i>Stroke</i> , 2004, 35, 458-463.	1.0	91
5	Atorvastatin Reduces the Expression of Prostaglandin E2 Receptors in Human Carotid Atherosclerotic Plaques and Monocytic Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 60-69.	0.8	70
6	Cellular Crosstalk between Endothelial and Smooth Muscle Cells in Vascular Wall Remodeling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7284.	1.8	69
7	Usefulness of a Combination of Monocyte Chemoattractant Protein-1, Galectin-3, and N-Terminal Probrain Natriuretic Peptide to Predict Cardiovascular Events in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2014, 113, 434-440.	0.7	66
8	TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases. <i>Frontiers in Immunology</i> , 2014, 5, 3.	2.2	60
9	TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 3648.	3.0	48
10	HMGB1 Expression and Secretion Are Increased Via TWEAK-Fn14 Interaction in Atherosclerotic Plaques and Cultured Monocytes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 612-620.	1.1	45
11	Oxidative Stress in Human Atherothrombosis: Sources, Markers and Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2315.	1.8	45
12	ApoA-I/HDL-C levels are inversely associated with abdominal aortic aneurysm progression. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1335-1346.	1.8	41
13	TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. <i>Cardiovascular Research</i> , 2015, 108, 139-147.	1.8	40
14	APOA1 oxidation is associated to dysfunctional high-density lipoproteins in human abdominal aortic aneurysm. <i>EBioMedicine</i> , 2019, 43, 43-53.	2.7	40
15	Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 721-734.	1.6	39
16	TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. <i>Cardiovascular Research</i> , 2011, 89, 225-233.	1.8	37
17	Complement C5 Protein as a Marker of Subclinical Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1926-1941.	1.2	32
18	From tissue iron retention to low systemic haemoglobin levels, new pathophysiological biomarkers of human abdominal aortic aneurysm. <i>Thrombosis and Haemostasis</i> , 2014, 112, 87-95.	1.8	30

#	ARTICLE	IF	CITATIONS
19	Quantitative HDL Proteomics Identifies Peroxiredoxin-6 as a Biomarker of Human Abdominal Aortic Aneurysm. <i>Scientific Reports</i> , 2016, 6, 38477.	1.6	29
20	Role of complement system in pathological remodeling of the vascular wall. <i>Molecular Immunology</i> , 2019, 114, 207-215.	1.0	29
21	Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease. <i>Atherosclerosis</i> , 2018, 270, 13-20.	0.4	22
22	Tumor Necrosis Factor-Like Weak Inducer of Apoptosis or Fn14 Deficiency Reduce Elastase Perfusion-Induced Aortic Abdominal Aneurysm in Mice. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	21
23	A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis. <i>EBioMedicine</i> , 2019, 46, 274-289.	2.7	21
24	Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges. <i>Cells</i> , 2020, 9, 405.	1.8	21
25	Fisiopatología del aneurisma de aorta abdominal: biomarcadores y nuevas dianas terapéuticas. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019, 31, 166-177.	0.4	20
26	The TNF-like weak inducer of the apoptosis/fibroblast growth factor-inducible molecule 14 axis mediates histamine and platelet-activating factor-induced subcutaneous vascular leakage and anaphylactic shock. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 583-596.e6.	1.5	19
27	Role of Extracellular Vesicles as Potential Diagnostic and/or Therapeutic Biomarkers in Chronic Cardiovascular Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 813885.	1.8	19
28	Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm. <i>Science Advances</i> , 2022, 8, eabm7322.	4.7	18
29	Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes. <i>Journal of Clinical Medicine</i> , 2020, 9, 1105.	1.0	15
30	N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease. <i>PLoS ONE</i> , 2015, 10, e0126741.	1.1	15
31	TWEAK blockade decreases atherosclerotic lesion size and progression through suppression of STAT1 signaling in diabetic mice. <i>Scientific Reports</i> , 2017, 7, 46679.	1.6	14
32	MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation. <i>Journal of Clinical Medicine</i> , 2021, 10, 1137.	1.0	14
33	Impaired HDL (High-Density Lipoprotein)-Mediated Macrophage Cholesterol Efflux in Patients With Abdominal Aortic Aneurysm—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2750-2754.	1.1	13
34	CD163 deficiency increases foam cell formation and plaque progression in atherosclerotic mice. <i>FASEB Journal</i> , 2020, 34, 14960-14976.	0.2	13
35	IgG Anti-High Density Lipoprotein Antibodies Are Elevated in Abdominal Aortic Aneurysm and Associated with Lipid Profile and Clinical Features. <i>Journal of Clinical Medicine</i> , 2020, 9, 67.	1.0	12
36	Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3037.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2835.	1.0	5
38	Malondialdehyde-modified HDL particles elicit a specific IgG response in abdominal aortic aneurysm. <i>Free Radical Biology and Medicine</i> , 2021, 174, 171-181.	1.3	3
39	Macrophage Cholesterol Efflux Downregulation Is Not Associated with Abdominal Aortic Aneurysm (AAA) Progression. <i>Biomolecules</i> , 2020, 10, 662.	1.8	2
40	N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 4042.	1.0	2
41	NT-proBNP Levels Influence the Prognostic Value of Mineral Metabolism Biomarkers in Coronary Artery Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 4153.	1.0	1